Somaxon Pharmaceuticals
Solana Beach, California, United States
About Somaxon Pharmaceuticals
Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketing proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Total funding: $94.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2009)
- Ticker: nasdaq:SOMX
- Website: somaxon.com
- Phone: +1 858-876-6500
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/somaxon-pharmaceuticals-2481455 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.